Michelle Gleason

1.6k total citations
11 papers, 1.3k citations indexed

About

Michelle Gleason is a scholar working on Immunology, Oncology and Hematology. According to data from OpenAlex, Michelle Gleason has authored 11 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Immunology, 4 papers in Oncology and 2 papers in Hematology. Recurrent topics in Michelle Gleason's work include Immune Cell Function and Interaction (10 papers), T-cell and B-cell Immunology (5 papers) and CAR-T cell therapy research (4 papers). Michelle Gleason is often cited by papers focused on Immune Cell Function and Interaction (10 papers), T-cell and B-cell Immunology (5 papers) and CAR-T cell therapy research (4 papers). Michelle Gleason collaborates with scholars based in United States, Japan and Germany. Michelle Gleason's co-authors include Jeffrey S. Miller, Michael R. Verneris, Valarie McCullar, Daniel A. Vallera, Bin Zhang, Louis M. Weiner, Angela Panoskaltsis‐Mortari, Bruce R. Blazar, Andres Wiernik and Erica D. Warlick and has published in prestigious journals such as Blood, Clinical Cancer Research and Molecular Cancer Therapeutics.

In The Last Decade

Michelle Gleason

11 papers receiving 1.3k citations

Peers

Michelle Gleason
Alexander J. Lenvik United States
Bartosz Grzywacz United States
Cécile Bonnafous France
Peter Hinderlie United States
Laura E. Bendzick United States
Jan Spanholtz Netherlands
Srinivas S. Somanchi United States
Matilde D’Asaro Italy
Kenneth F. May United States
Susann Szmania United States
Alexander J. Lenvik United States
Michelle Gleason
Citations per year, relative to Michelle Gleason Michelle Gleason (= 1×) peers Alexander J. Lenvik

Countries citing papers authored by Michelle Gleason

Since Specialization
Citations

This map shows the geographic impact of Michelle Gleason's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michelle Gleason with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michelle Gleason more than expected).

Fields of papers citing papers by Michelle Gleason

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michelle Gleason. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michelle Gleason. The network helps show where Michelle Gleason may publish in the future.

Co-authorship network of co-authors of Michelle Gleason

This figure shows the co-authorship network connecting the top 25 collaborators of Michelle Gleason. A scholar is included among the top collaborators of Michelle Gleason based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michelle Gleason. Michelle Gleason is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
2.
Ross, Julie A., Jakub Tolar, Logan G. Spector, et al.. (2014). An Exploratory Analysis of Mitochondrial Haplotypes and Allogeneic Hematopoietic Cell Transplantation Outcomes. Biology of Blood and Marrow Transplantation. 21(1). 81–88. 7 indexed citations
3.
Gleason, Michelle, Julie A. Ross, Erica D. Warlick, et al.. (2014). CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood. 123(19). 3016–3026. 208 indexed citations
4.
Vallera, Daniel A., Bin Zhang, Michelle Gleason, et al.. (2013). Heterodimeric Bispecific Single-Chain Variable-Fragment Antibodies Against EpCAM and CD16 Induce Effective Antibody-Dependent Cellular Cytotoxicity Against Human Carcinoma Cells. Cancer Biotherapy and Radiopharmaceuticals. 28(4). 274–282. 82 indexed citations
5.
Wiernik, Andres, Bree Foley, Bin Zhang, et al.. (2013). Targeting Natural Killer Cells to Acute Myeloid LeukemiaIn Vitrowith a CD16 × 33 Bispecific Killer Cell Engager and ADAM17 Inhibition. Clinical Cancer Research. 19(14). 3844–3855. 176 indexed citations
6.
Gleason, Michelle, Todd Lenvik, Valarie McCullar, et al.. (2012). Tim-3 Is an Inducible Human Natural Killer (NK) Cell Receptor That Enhances Interferon Gamma Production in Response to Galectin-9 (GAL-9). Biology of Blood and Marrow Transplantation. 18(2). S273–S273. 1 indexed citations
7.
Gleason, Michelle, Michael R. Verneris, D.A. Todhunter, et al.. (2012). Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production. Molecular Cancer Therapeutics. 11(12). 2674–2684. 192 indexed citations
8.
Gleason, Michelle, Todd Lenvik, Valarie McCullar, et al.. (2012). Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood. 119(13). 3064–3072. 303 indexed citations
9.
Godal, Robert, Veronika Bachanová, Michelle Gleason, et al.. (2010). Natural Killer Cell Killing of Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia Blasts by Killer Cell Immunoglobulin-Like Receptor–Negative Natural Killer Cells after NKG2A and LIR-1 Blockade. Biology of Blood and Marrow Transplantation. 16(5). 612–621. 79 indexed citations
10.
Cooley, Sarah, Michelle Gleason, Valarie McCullar, et al.. (2007). A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature. Blood. 110(2). 578–586. 178 indexed citations
11.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alexander J. Lenvik Breakdown of academic impact, for papers by Bartosz Grzywacz Breakdown of academic impact, for papers by Cécile Bonnafous Breakdown of academic impact, for papers by Peter Hinderlie Breakdown of academic impact, for papers by Laura E. Bendzick Breakdown of academic impact, for papers by Jan Spanholtz Breakdown of academic impact, for papers by Srinivas S. Somanchi Breakdown of academic impact, for papers by Matilde D’Asaro Breakdown of academic impact, for papers by Kenneth F. May Breakdown of academic impact, for papers by Susann Szmania
Rankless by CCL
2026